B7族同源体3、过氧化物酶1、硫氧还蛋白在溃疡性结肠炎及其相关性结直肠癌患者血清和组织中的表达及意义

doi:10.3969/j.issn.1006-5725.2025.09.020

Abstract

Abstract:

Objective To investigate the expression levels and clinical significance of B7 homolog 3（B7-H3）， peroxiredoxin 1 （PRDX1）， and thioredoxin （TRX） in the serum and tissues of patients with ulcerative colitis （UC） and UC-associated colorectal cancer （UC-CRC）. Methods A total of 108 patients with UC who underwent examination in our hospital between January 2019 and December 2023 were enrolled in the UC group. Additionally， 108 patients with UC-CRC who were examined in our hospital were included in the UC-CRC group. Furthermore， 108 individuals without any abnormalities detected during colonoscopy were recruited as the control group. The serum levels of B7-H3， PRDX1， and TRX were quantified using enzyme-linked immunosorbent assay （ELISA）. The expression of B7-H3， PRDX1， and TRX in tissues from UC-CRC and UC patients was assessed by immunohistochemistry. The diagnostic performance of serum B7-H3， PRDX1， and TRX levels for UC-CRC was evaluated by constructing receiver operating characteristic （ROC） curves. Results Compared with the control group， the serum expression levels of B7-H3， PRDX1， and TRX in both the UC group and the UC-CRC group were significantly elevated in sequence （P < 0.05）. In comparison to the resting UC group， the serum expression levels of B7-H3， PRDX1， and TRX in the episodic UC group also increased significantly （P < 0.05）. Furthermore， compared with UC patients， the positive expression rates of B7-H3， PRDX1， and TRX in the tissues of UC-CRC patients were markedly higher （P < 0.05）. The combination of serum B7-H3， PRDX1， and TRX demonstrated the highest AUC for diagnosing UC-CRC patients， outperforming the individual diagnostic performance of each biomarker （Z_{combination-B7-H3} = 2.829， P = 0.005， Z_{combination-PRDX1} = 2.544， P = 0.011， Z_{combination-TRX} = 3.673， P < 0.001）. Conclusion B7-H3， PRDX1， and TRX are significantly overexpressed in both the serum and tissues of UC-CRC patients， and their combined evaluation holds potential as a diagnostic tool for detecting the development of UC-CRC.

Key words: B7 homolog 3, peroxiredoxin 1, thioredoxin, ulcerative colitis, colorectal cancer

CLC Number:

R735.34

Na WU,Zetian ZHANG,Rui WANG. The expression and clinical significance of B7⁃H3， PRDX1， and TRX in the serum and tissues of patients with ulcerative colitis and its related colorectal cancer[J]. The Journal of Practical Medicine, 2025, 41(9): 1407-1412.

Figures/Tables 8

Fig.1

Tab.1

Tab.2

Tab.3

Tab.4

Fig.2

Fig.3

Tab.5

References 26

1	万捷. 溃疡性结肠炎组织学炎症负担评估与结直肠癌及癌前病变的相关性研究［D］.济南：山东大学， 2021.
2	李媛，戚务芳.溃疡性结肠炎及相关结直肠癌组织中CD147和Oct-4及Sox-2的表达及其相关性［J］.中国临床药理学杂志， 2019， 35（19）：2321-2323， 2327.
3	吴振兴，陈文晓，彭玄杰. 血清炎性因子与溃疡性结肠炎相关性结直肠癌发生的相关性分析［J］.现代实用医学， 2017， 29（1）：34-35.
4	刘维新，张绅，任益，等.溃疡性结肠炎及溃疡性结肠炎相关性结直肠癌小鼠模型中血管生成因子的表达及其与血管新生的关系［J］.中国医科大学学报， 2013， 42（3）：231-234， 266.
5	蔡惠民.溃疡性结肠炎相关性结直肠癌存活率低于散发性结直肠癌［J］.中国普外基础与临床杂志， 2012， 19（5）：506.
6	OKAYASU I. Development of ulcerative colitis and its assosiated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence［J］. Pathlo Int， 2012， 62（6）：368-380. doi:10.1111/j.1440-1827.2012.02807.x doi: 10.1111/j.1440-1827.2012.02807.x
7	LI Y， CAI Q， SHEN X， et al. Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal Cancer［J］. Front Oncol， 2021， 11（1）：1-12. doi:10.3389/fonc.2021.759528 doi: 10.3389/fonc.2021.759528
8	ZHANG Y， WU X， WU J， et al. Decreased expression of microRNA-510 in intestinal tissue contributes to postinfectious irritable bowel syndrome via targeting PRDX1［J］. Am J Transl Res， 2019， 11（12）：7385- 7397.
9	王海鹏，刘同帅，于群，等. Prdx1基因敲减促进氧糖剥夺/复氧诱导的小鼠神经母细胞瘤N2a细胞凋亡［J］. 中国病理生理杂志， 2021， 37（8）：1422-1429.
10	杨婕琳，王晓媛，李海霞. TRX和TXNIP在结直肠癌组织中的表达及其交互作用［J］. 检验医学， 2023， 38（4）：330-336.
11	SHAW S Y， BLANCHARD J F， BERNSTEIN C N. Early childhood measles vaccinations are not associated with paediatric IBD：a population-based analysis［J］. J Crohns Colitis， 2015， 9（4）：334-338. doi:10.1093/ecco-jcc/jjv029 doi: 10.1093/ecco-jcc/jjv029
12	中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见（2018年·北京）［J］. 中国实用内科杂志， 2018， 38（9）： 796-813.
13	庞雪，郭建壮. 溃疡性结肠炎发病机制的单细胞转录组生物信息学研究［J］. 实用医学杂志， 2024， 40（15）：2075-2083.
14	HUANG L， ZHOU Y， SUN Q， et al. Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma［J］. Cancer Biomark， 2022， 33（1）：123-129. doi:10.3233/cbm-210178 doi: 10.3233/cbm-210178
15	FLEM-KARLSEN K， FODSTAD Ø， TAN M， et al. B7-H3 in Cancer- Beyond Immune Regulation［J］. Trends Cancer， 2018， 4（6）： 401-404. doi:10.1016/j.trecan.2018.03.010 doi: 10.1016/j.trecan.2018.03.010
16	FENG R， CHEN Y， LIU Y， et al. The role of B7-H3 in tumors and its potential in clinical application［J］. Int Immunopharmacol， 2021， 101（1）：1-13. doi:10.1016/j.intimp.2021.108153 doi: 10.1016/j.intimp.2021.108153
17	倪佳敏，李刚，鲍军. EphA2与B7-H3在结直肠癌组织中表达及其与临床病理和预后的相关性［J］. 现代消化及介入诊疗， 2023， 28（7）：833-838.
18	杨保伟，林力森，周海娟，等. 腹泻型肠易激综合征患者肠黏膜PRDX1、FXR的表达及其相关性分析［J］. 中国现代医学杂志， 2021， 31（12）：40-45.
19	GUO W， LIU X， LI J， et al. Prdx1 alleviates cardiomyocyte apoptosis through ROS-activated MAPK pathway during myocardial ischemia/reperfusion injury［J］. Int J Biol Macromol， 2018， 112（1）： 608-615. doi:10.1016/j.ijbiomac.2018.02.009 doi: 10.1016/j.ijbiomac.2018.02.009
20	ZHANG Y， WU X X， LI S， et al. Peroxiredoxin 1 as an inflammatory marker in diarrhea-predominant and postinfectious irritable bowel syndrome［J］. Neurogastroenterol Motil， 2020， 32（2）： 1-13. doi:10.1111/nmo.13741 doi: 10.1111/nmo.13741
21	青青，张绍衡，谢玥，等. 肝素类药物对炎症性肠病患者治疗有效性与安全性的Meta分析［J］. 重庆医学， 2020， 49（10）：1681-1686.
22	董勇，杨文义，华静，等. 血清CCL11、PRDX1水平与炎症性肠病患者肠道菌群、肠黏膜屏障功能的相关性［J］. 胃肠病学和肝病学杂志， 2023， 32（5）：514-518.
23	杨岚，代海燕，鞠传余. 硫氧还蛋白（Trx）对糖尿病视网膜病变模型鼠血清补体Clq肿瘤坏死因子相关蛋白9（CTRP9）表达的影响［J］. 眼科新进展， 2019， 39（3）：229-233.
24	杨婕琳，陈文婷，高会斌. 硫氧还蛋白及其相互作用蛋白在结直肠腺瘤中的表达及意义［J］. 肿瘤学杂志， 2021， 27（5）： 409-411.
25	HORIE K， MIKAMI T， YOSHIDA T， et al. Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry［J］. Oncol Lett， 2018， 15（2）： 2364-2372.
26	SABZEVARY-GHAHFAROKHI M， SHOHAN M， SHIRZAD H， et al. The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis［J］. Pathol Res Pract， 2018， 214（8）：1149-1155. doi:10.1016/j.prp.2018.06.001 doi: 10.1016/j.prp.2018.06.001

组别	UC组（n = 108）	UC-CRC组（n = 108）	对照组（n = 108）	F/χ² 值	P值
年龄（x ± s）/岁	49.62 ± 7.54	48.95 ± 7.46	48.62 ± 7.35	0.593	0.553
性别/例				0.174	0.917
男	56	59	57
女	52	49	51
体质量指数（x ± s）/（kg/m²）	22.76 ± 2.12	22.51 ± 2.23	22.89 ± 2.04	0.887	0.413
糖尿病史/［例（%）］	8（7.4）	13（12.0）	11（10.2）	1.318	0.517
高血压史/［例（%）］	12（11.1）	15（13.9）	9（8.3）	1.688	0.430
吸烟史/［例（%）］	19（17.6）	21（19.4）	16（14.8）	0.820	0.664
饮酒史/［例（%）］	16（14.8）	19（17.6）	17（15.7）	0.321	0.852

组别	B7-H3	PRDX1	TRX
UC组（n = 108）	21.34 ± 4.76^?	103.62 ± 17.35^?	176.35 ± 21.86^?
UC-CRC组（n = 108）	35.18 ± 5.29^?△	124.35 ± 18.67^?△	216.45 ± 24.71^?△
对照组（n = 108）	16.61 ± 3.26	84.32 ± 15.44	132.61 ± 20.27
F值	492.469	146.230	379.985
P值	< 0.001	< 0.001	< 0.001

组别	B7-H3/（ng/mL）	PRDX1/（ng/mL）	TRX/（ng/mL）
静息期UC组（n = 36）	18.76 ± 4.70	89.13 ± 16.22	156.43 ± 20.31
发病期UC组（n = 72）	22.63 ± 4.79	110.87 ± 17.91	186.31 ± 22.64
t值	3.983	6.131	6.685
P值	< 0.001	< 0.001	< 0.001

组别	例数	B7-H3		PRDX1		TRX
组别	例数	阴性	阳性	阴性	阳性	阴性	阳性
UC组	108	89（82.41）	19（17.59）	84（77.78）	24（22.22）	88（81.48）	20（18.52）
UC-CRC组	108	35（32.41）	73（67.59）	29（26.85）	79（73.15）	31（28.70）	77（71.30）
χ² 值		55.212		56.139		60.797
P值		< 0.001		< 0.001		< 0.001

变量	AUC	截断值（ng/mL）	95%CI	敏感度（%）	特异度（%）	Youden指数
B7-H3	0.825	33.516	0.767~0.873	69.44	82.41	0.519
PRDX1	0.820	120.951	0.762~0.869	63.89	88.89	0.528
TRX	0.790	211.146	0.729~0.842	62.96	85.19	0.482
三者联合	0.912		0.866~0.946	91.67	80.56	0.722

The expression and clinical significance of B7⁃H3， PRDX1， and TRX in the serum and tissues of patients with ulcerative colitis and its related colorectal cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 26

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Likun WANG,Qi HAO,Weihan JIN,Shizheng DONG,Xueliang WU,Xiaofeng HU,Liang WU,Jing XUN,Hongqing MA. Application of multi⁃omics and artificial intelligence in the prediction and diagnosis of liver metastases in colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 1070-1078.
[2]	Linsha KONG,Gaigai HE,Ting LI,Kun FANG,Wei HE,Li WEI. Experimental study of doxorubicin coated by magnetic drug⁃carrying gel beads in the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 953-959.
[3]	Wei WANG,Min WANG,Minmin CHENG,Tingting. ZHANG. Impacts of safflower polysaccharide on tumor growth and PI3K/Akt/mTOR signal pathway in mice with colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(5): 670-675.
[4]	Jiyue ZHU,Bo ZHANG,Yaru LI,Liuye. HUANG. The predictive value of the systemic inflammation response index for non⁃curative resection after endoscopic submucosal dissection for early colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(5): 716-723.
[5]	Wenying SHANG,Die LONG,Haihui CHEN. Real⁃world analysis of the differences between left and right colorectal cancer based on clinical pathological characteristics and gene testing results [J]. The Journal of Practical Medicine, 2025, 41(1): 48-52.
[6]	Rongmao HE,Zeyang FANG,Yunyun ZHANG,Youliang WU,Shixiu LIANG,Siqi WANG. Protective effect of basic alkaline ceramidase 1 in ulcerative colitis [J]. The Journal of Practical Medicine, 2025, 41(1): 7-14.
[7]	Yuxuan DING,Lining GUO,Jiayi SHEN,Lijun. WANG. Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases [J]. The Journal of Practical Medicine, 2024, 40(9): 1293-1297.
[8]	Yin HUA,Xiaoyan WANG,Zhen WANG,Yongning XIN,Shousheng. LIU. The relationship between ulcerative colitis and the risk of hypothyroidism： A two⁃mendelian randomization study [J]. The Journal of Practical Medicine, 2024, 40(6): 827-832.
[9]	Yujun YI,Xiaoming ZHAI,Huiling LIU,Jin. TAO. The role of PTTG1 in colonic inflammation by regulating intestinal epithelial cells pyroptosis [J]. The Journal of Practical Medicine, 2024, 40(5): 632-638.
[10]	Wei DENG,Dan PENG,Haijun HU,Jing ZHANG,Shuchun YU,Song. HUANG. Application of general anesthesia under nociception index combined with BIS monitoring in laparoscopic radical resection of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(24): 3476-3481.
[11]	Xiuli SHI,Jiaqi CHEN,Fan ZHU,Juan ZENG,Na. WU. The effect of miR⁃143⁃3p on pyroptosis of ulcerative colitis cells by regulating TLR2/NF⁃κB/NLRP3 [J]. The Journal of Practical Medicine, 2024, 40(15): 2056-2062.
[12]	Xue PANG,Jianzhuang. GUO. Single-cell transcriptomic bioinformatics study of the pathogenesis of ulcerative colitis [J]. The Journal of Practical Medicine, 2024, 40(15): 2075-2083.
[13]	Mingxin TANG,Xiaolin WANG,Xuanfei. LI. Research progress of statins in the prevention and treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(14): 2041-2046.
[14]	LI Xiaoping, ZHOU Hongjian, GAO Fangfang, LI Wei.. Tspan1 antagonizes oxaliplatin⁃induced apoptosis in colorectal cancer cells by inducing cellular autophagy [J]. The Journal of Practical Medicine, 2023, 39(9): 1072-1078.
[15]	HAO Jian, HAN Lei.. Diagnostic value of single and combined panel of serum exosomal microRNAs in colorectal cancer [J]. The Journal of Practical Medicine, 2023, 39(3): 364-373.